Working… Menu

Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients (PSA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02058680
Recruitment Status : Unknown
Verified September 2018 by OncBioMune Pharmaceuticals.
Recruitment status was:  Active, not recruiting
First Posted : February 10, 2014
Last Update Posted : September 10, 2018
United States Department of Defense
Information provided by (Responsible Party):
OncBioMune Pharmaceuticals

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018